von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report
TH Open · 06.06.2025 · 09 (CP)
DOI: 10.1055/a-2606-9625 ↗Kurz gefasst
Fallbericht in der Zeitschrift TH Open, erschienen am 06.06.2025. Verfasst von Claudia Djambas Khayat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Octapharma AG, Lachen, Switzerland.
Abstract (Originalsprache)
The development of inhibitors to von Willebrand factor (VWF) is a rare but potentially serious complication of VWF replacement therapy in patients with von Willebrand disease (VWD). Patients who develop VWF inhibitors may become unresponsive and/or may develop severe anaphylactic reactions to VWF concentrates. Data on inhibitor development and management in VWD remain limited, and better understanding of inhibitor development is an important goal in VWD management. The WIL-31 study demonstrated the efficacy and safety of prophylaxis with wilate, a plasma-derived VWF/factor VIII (pdVWF/FVIII) concentrate, in children and adults with VWD of all types. The annualized bleeding rate (ABR) was reduced by 84% with wilate prophylaxis compared with on-demand treatment, and prophylaxis was well tolerated. No inhibitors developed during the WIL-31 study. Here, we report two brothers with type 3 VWD who at the 6-month visit were found to have VWF inhibitors, which on further investigation were found to have already been present before the study. Despite the presence of inhibitors, neither patient showed any clinical symptoms, and prophylaxis with wilate led to a ≥85% reduction in ABR in both boys compared with on-demand treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.
- Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
- Octapharma USA, Paramus, New Jersey, United States.
- Octapharma AG, Lachen, Switzerland.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States.
Förderung
- Octapharma AG, Lachen, Switzerland
Zitieren
APA
Djambas Khayat, C., Pavlova, A., Werner, S., Knaub, S., & Sidonio, R. F. (2025). von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report. TH Open, 09(CP). https://doi.org/10.1055/a-2606-9625
Vancouver
Djambas Khayat C, Pavlova A, Werner S, Knaub S, Sidonio RF. von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report. TH Open. 2025;09(CP). doi:10.1055/a-2606-9625
BibTeX
@article{DjambasKhayat2025,
author = {Djambas Khayat, Claudia and Pavlova, Anna and Werner, Sylvia and Knaub, Sigurd and Sidonio, Robert F},
title = {von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report},
journal = {TH Open},
year = {2025},
volume = {09},
number = {CP},
doi = {10.1055/a-2606-9625}
}
EUVIMED